Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: AgAuUSA who wrote (9583)	7/1/1998 1:45:00 PM
From: Scott H. Davis	Read Replies (2) \| Respond to of 14328

Greg, that really is a red herring response. If you're going to refute, do it with facts, otherwise it serves as no help to any others considering investing in or selling TRIBY. If it does anything, it costs credibility. IMSCO Scott

To: AgAuUSA who wrote (9583)	7/1/1998 1:48:00 PM
From: dowman	Read Replies (1) \| Respond to of 14328

My information is correct. Call Sanofi, who holds the patent, or JNJ or ABT who hold the license. Or for that matter, call people involved in this issue such as the FDA or someone at the CDC and ask them. Or for that matter call others that would love to hold the license and I know are trying to obtain the license such as Calypte or Epitope. You made up your mind in the eighties, but things have changed. You can never learn anything new by seeking out those who already agree with you. This is a huge issue for approval unless the FDA changes their position. I have seen it posted hear that the last conference call disclosed that the company did not expect approval for the test this year. This is the reason